Shilpa Medicare spurts after Bengaluru facility gets GMP certificate

13 Jul 2022 , 10:20 AM

Shilpa Medicare said that its newly commissioned facility for manufacture and testing of Orodispersible films and Transdermal systems situated at Dabaspet, Bengaluru in Karnataka, has been issued GMP Certificate by UK Medicines and Healthcare products Regulatory Agency (MHRA). The facility was inspected by MHRA from 18 April 2022 to 20 April 2022. The facility has capabilities of manufacturing and testing specialized dosage forms like Orodispersible Films and Transdermal systems. It is backed up with strong Research and Development of challenging orodispersible films and transdermal technologies. The GMP facility is equipped with state of art infrastructure to meet commercial requirements from a global perspective. Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets. Shilpa Medicares consolidated net profit surged 277% to Rs 29.55 crore on 63.7% increase in net sales to Rs 340.60 crore in Q4 FY22 over Q4 FY21. Powered by Capital Market – Live News